Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 TrialWilliam Greenhalf, Markus W. Büchler, Richard F. Lamb et al.|JNCI Journal of the National Cancer Institute|2013Cited by 333
Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trialGary Middleton, John P. Neoptolemos, Daniel H. Palmer et al.|The Lancet Oncology|2017Cited by 73
Identification of Cystic Lesions by Secondary Screening of Familial Pancreatic Cancer (FPC) Kindreds Is Not Associated with the Stratified Risk of CancerAndrea Sheel, Sara Harrison, Ioannis Sarantitis et al.|The American Journal of Gastroenterology|2018Cited by 33